Halozyme Therapeutics’ (HALO) “Buy” Rating Reaffirmed at HC Wainwright

Halozyme Therapeutics (NASDAQ:HALO)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $70.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 24.38% from the company’s previous close.

Several other equities research analysts have also recently commented on HALO. Wells Fargo & Company cut their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. JMP Securities upped their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Piper Sandler lifted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Finally, Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $60.89.

Halozyme Therapeutics Stock Down 0.6 %

Shares of NASDAQ HALO opened at $56.28 on Tuesday. The stock has a market cap of $7.16 billion, a PE ratio of 18.64, a P/E/G ratio of 0.43 and a beta of 1.25. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics has a 12-month low of $33.15 and a 12-month high of $65.53. The company has a 50-day moving average of $50.82 and a 200 day moving average of $54.33.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now directly owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 2.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Several large investors have recently bought and sold shares of the business. AQR Capital Management LLC raised its position in shares of Halozyme Therapeutics by 5.0% during the 2nd quarter. AQR Capital Management LLC now owns 47,773 shares of the biopharmaceutical company’s stock worth $2,501,000 after acquiring an additional 2,265 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $1,075,000. SG Americas Securities LLC grew its position in shares of Halozyme Therapeutics by 365.6% in the 3rd quarter. SG Americas Securities LLC now owns 12,186 shares of the biopharmaceutical company’s stock valued at $698,000 after buying an additional 9,569 shares during the last quarter. Park Avenue Securities LLC lifted its position in Halozyme Therapeutics by 25.2% in the third quarter. Park Avenue Securities LLC now owns 11,638 shares of the biopharmaceutical company’s stock valued at $666,000 after acquiring an additional 2,343 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 350 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.